NCT01565395View on ClinicalTrials.gov

Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Parkinson DiseaseAmyotrophic Lateral Sclerosis
Interventions
DRUG

Incobotulinum Toxin A

Xeomin 70-100 units injected in the parotid and submandibular glands of subjects

DRUG

placebo

Sterile preservative free 0.9% saline

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

Merz Pharmaceuticals
All Listed Sponsors
collaborator

Merz Pharmaceuticals

INDUSTRY

lead

Beth Israel Deaconess Medical Center

OTHER

NCT01565395 - Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter | Biotech Hunter